Search Results
Your search for ,ouT matches 5632 pages
Showing 2401 - 2450Incoming ASCO President Sets His Sights on Conquering Cancer
For more than 3 decades, Howard A. “Skip” Burris III, MD, FACP, FASCO, has dedicated his medical career to researching the development of chemotherapies for breast cancer, including ado-trastuzumab emtansine, everolimus, and gemcitabine. In addition, he is credited with changing the standard of...
American Cancer Society Sets 2035 Cancer Mortality Reduction Goal
The American Cancer Society (ACS) has set a challenge goal to reduce overall cancer mortality 40% between 2015 and 2035—a goal set by applying favorable cancer mortality trends among college graduates to the population as a whole. A report on the goal was published by Ma et al in CA: A...
FDA Pipeline: Designations in Myeloma, Adenoid Cystic Carcinoma, and Kaposi Sarcoma, Plus ODAC Votes
This week, the U.S. Food and Drug Administration granted designations in relapsed or refractory multiple myeloma, adenoid cystic carcinoma, and Kaposi sarcoma; and the FDA’s Oncologic Drugs Advisory Committee (ODAC) held votes on treatments for tenosynovial giant cell tumor and acute...
2019 ASCO: Entrectinib in Children and Adolescents With Recurrent or Refractory Solid or Central Nervous System Tumors
A phase I/IB study evaluating the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors, including central nervous system (CNS) tumors, has found that the agent produced responses in children with tumors harboring target aberrations...
Postprogression Treatment of Estrogen Receptor–Positive Breast Cancer: Future Approaches
AT THE 2019 Miami Breast Cancer Conference, William J. Gradishar, MD, FASCO, presented a vision of the future in the treatment of advanced hormone receptor–positive breast cancer.1 The refinement of disease subsets, the development of agents targeting the PI3K/AKT/mTOR pathway, the use of novel...
Dual-Immunotherapy Approach Shows Efficacy in High-Grade Neuroendocrine Tumors
COMBINING TWO established immunotherapy agents achieved tumor shrinkage in rare, aggressive, extrapancreatic high-grade neuroendocrine tumors, according to the results of SWOG S1609, a phase II clinical basket trial also known as DART (Dual Anti– CLTA-4 and Anti–PD-1 Blockade in Rare Tumors). The...
Harnessing the Power of Twitter for Clinical Trial Enrollment and Success
CLINICAL TRIALS are vital for advancing cancer care for our patients. Each trial represents an unanswered problem for which researchers are committed to solving. Designing, funding, recruiting, and completing a trial are tremendous undertakings for each researcher, physician, patient, and...
PRRT Shows Long-Term Effectiveness in Malignant Neuroendocrine Tumors
A 12-year retrospective clinical study of patients who received peptide receptor radionuclide therapy (PRRT) for malignant neuroendocrine tumors demonstrated the long-term effectiveness of this treatment, which also allows patients to maintain a high quality of life. The study was published by...
IMPACT Study, Aimed at Increasing Diversity Among Clinical Trial Participants, Launches
The University of Southern California (USC) Norris Comprehensive Cancer Center has launched a study to determine how financial assistance for costs associated with clinical trial participation might increase enrollment, particularly among low-income patients and racial and ethnic minorities....
AUA 2019: Studies Highlight Potential Bladder Cancer Risks
Electronic cigarettes (e-cigarettes), exposure to certain environmental factors, and human papillomavirus (HPV) infection may increase the risk of developing bladder cancer, according to new data presented this week at the 2019 Annual Meeting of the American Urological Association (AUA). The...
ASBrS 2019: Factors Associated With Nonoperative Management of Select Patients With HER2-Positive Breast Cancer
Tumor hormonal status, possible ductal carcinoma in situ (DCIS) on initial biopsy, and imaging results following neoadjuvant chemotherapy may help physicians predict whether surgery might be safely eliminated for HER2-positive breast cancer that is traditionally treated aggressively....
ESTRO 38: REQUITE Project Finds Predictive Biomarkers for Late Radiotherapy Toxicity
The latest results from the REQUITE project, which aimed to discover what makes patients more likely to experience adverse effects after radiotherapy, have shown that a combination of biologic markers and certain genetic changes can predict radiation sensitivity. In addition, the international team ...
ESTRO 38: What Type of Radiotherapy May Best Preserve Cognitive Function in Pediatric Patients With Brain Tumors?
A comparison of three types of radiotherapy for pediatric brain tumors suggests that a type of proton therapy called pencil-beam scanning (PBS) offers the best hope of preserving cognitive functions. The study, presented by Toussaint et al at ESTRO 38, the annual congress of the European Society...
ESTRO 38: Long-Term Results of Adjuvant Radiotherapy Plus Antihormonal Treatment in Hormone Receptor–Positive Breast Cancer
Women with early-stage, low-risk, hormone receptor–positive breast cancer may be less likely to experience disease recurrence if they have radiotherapy after surgery as well as antihormonal treatment, according to results from a trial that has followed 869 women for 10 years. These findings...
Psychosocial Care Is a Critical Component of Value-Based Oncology
The ongoing dialogue regarding health-care payment reform that attempts to incentivize high-value care by linking reimbursement to quality rather than quantity has largely ignored the ultimate consumer/buyer—the patient. Yet, in the minds of clinicians, policymakers, and the public at large,...
Hope and Fear Are Two Constants in the Lives of Patients With Cancer
A year and a half ago, when I was 33, the thought of having a life-threatening disease was unimaginable. In hindsight, the weight loss I began experiencing in the fall of 2017 should have raised concern because I’ve always had to be mindful of my diet if I wanted to lose weight. But denial can be a ...
Physician Identity and Physician Wellness Are Inextricably Linked
Imagine a 70-year-old patient who is scheduled for a pancreaticoduodenectomy. On the morning of surgery, the patient is checked in at the front desk by the “data-entry provider.” The patient is taken to the preoperative area, where the appropriate formalities are completed by multiple “bedside-care ...
ESMO Breast Cancer 2019: ONCOLLEGE-001: Global Survey of HER2 Testing
A global survey of HER2 testing has raised questions about how resources should be spent on potentially lifesaving HER2-targeted therapies for breast cancer, especially in lower-income countries. These results will be presented at the European Society for Medical Oncology (ESMO) Breast Cancer...
Erlotinib Plus Bevacizumab vs Erlotinib Alone in EGFR-Positive, Advanced Nonsquamous NSCLC
In an interim analysis of the phase III NEJ026 trial reported in The Lancet Oncology, Saito et al found that the addition of bevacizumab to erlotinib improved progression-free survival in patients with EGFR-positive, nonsquamous non–small cell lung cancer (NSCLC). In the open-label...
Expert Point of View: Rafael Fonseca, MD
Rafael Fonseca, MD, the Getz Family Professor of Cancer and Chair of the Department of Medicine, Mayo Clinic in Arizona and an expert in minimal residual disease (MRD) in myeloma, commented on the PRIMeR study for The ASCO Post. The PRIMeR subanalysis of the STaMINA trial showed the prognostic...
Young People Get Lung Cancer, Too
I’ve been in excellent physical shape my whole life. Growing up, it was my dream to play Division 1 soccer in college, and I trained hard throughout high school to achieve that goal. My dream came true, in 2005, when I was invited to play soccer at East Carolina University. I was eager to bond...
Mitigating Frailty and Sarcopenia to Improve Treatment Outcomes in Lung Cancer
Frailty and sarcopenia are common conditions among patients with lung cancer and are linked with decreased survival as well as increased surgical complications, chemotherapy toxicity, and cost of care. If a survey of oncologists at the 2019 Multidisciplinary Thoracic Cancers Symposium is any...
The Boy I Never Knew
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
The Evolving Role of Pathologists in the Diagnosis and Treatment of Cancer
In the past, the role of the pathologist was primarily to present anatomic pathology findings on various specimens, particularly at tumor boards. However, in the emerging age of personalized medicine and molecular diagnostics, the responsibilities of pathologist have greatly expanded into...
Expert Point of View: High-Risk Smoldering Multiple Myeloma
IN SPITE of the high response rates and lack of progression to active disease with the regimens described at the 2018 American Society of Hematology Meeting & Exposition, several myeloma experts interviewed by The ASCO Post said the data do not yet move them to routinely intervene in high-risk...
House Calls With Her Physician Father Sparked an Interest in Palliative Care for Janet L. Abrahm, MD
Nationally regarded palliative care expert Janet L. Abrahm, MD, was born and reared in San Francisco. Her father was a solo practitioner who saw medicine as a great profession. “My father would come home from his office for dinner and when he finished, he’d do house calls, often bringing us with...
The Microbiome: The Next Target in Cancer Therapy
With the recent breakthroughs in immunotherapy, treatments that modulate the immune system are now being used across numerous cancer types and across the spectrum of disease with significant success, but not all patients achieve objective responses. There is still a critical need to better...
NRG1 Gene Fusions Detected at Low Incidence Across Multiple Tumor Types
A consortium of researchers have completed an analysis of a new gene fusion they believe is responsible for the development of a wide spectrum of cancer types. According to the investigators, their studies show that errant gene fusions in neuregulin-1, or NRG1, which are present in about...
Collaborative Telerehabilitation in Patients With Advanced Cancer
Recent research suggests that remotely delivering rehabilitation services to patients with advanced cancer may improve their physical function, pain, and quality of life, while allowing them to spend less time in hospitals and nursing homes. These findings were published by Cheville et al in JAMA...
I Was Not Prepared for the Emotional Toll of Cancer
In 1996, an excruciating sore throat sent me first to my primary care physician and then to an ear, nose, and throat specialist, after a suspicious mass was found on the right side of my throat. A biopsy determined that the tumor was squamous cell neck cancer, and additional tests of my neck,...
Human Gene Therapy: Progress and Oversight
The early debate over the social and ethical implications of gene therapy led the National Institutes of Health (NIH) to establish the Recombinant DNA Advisory Committee in 1974. However, the risks of human gene therapies were largely unknown until 1999, when a patient died of a massive immune...
Anti–TIM-3 Antibody Well Tolerated as Monotherapy and in Combination With Anti–PD-L1 Antibody
INITIAL DATA from the ongoing, multicenter, first-in-human, phase Ia/Ib dose-escalation and -expansion study suggest that an anti–T-cell immunoglobulin domain and mucin domain–containing molecule 3 (anti–TIM-3) antibody alone or in combination with immune checkpoint blockade could counter intrinsic ...
Advanced HER2-Positive Breast Cancer: All Eyes on These Novel Agents
NEW AGENTS for the treatment of advanced HER2-positive breast cancer should be coming soon to your clinic, according to Sara A. Hurvitz, MD, Director of the Breast Cancer Clinical Research Program and Associate Professor of Medicine at the David Geffen School of Medicine at the University of...
Fine-Tuning an ‘Airport Diagnosis’
HIS HEAD WAS DIFFERENT from those of the other people in line. He bore a matrix of white rows of circular patches on his shaved scalp like a wig. The patches were electrodes, connected by cords to a power supply in a satchel around his shoulder. I was able to make an instant and unfortunate...
VISTA Checkpoint Implicated in Pancreatic Cancer Immunotherapy Resistance
Researchers have identified a new potential immunotherapy target in pancreatic cancer, which so far has been notoriously resistant to treatment with immune checkpoint blockade drugs effective against a variety of other cancers. A research team from The University of Texas MD Anderson Cancer Center...
Expert Point of View: Christopher L. Hallemeier, MD, and Andrew S. Kennedy, MD
Christopher L. Hallemeier, MD, Associate Professor in Radiation Oncology at the Mayo Clinic, Rochester, and Andrew S. Kennedy, MD, Physician in Chief of Radiation Oncology at Sarah Cannon, Nashville, and Director of Radiation Oncology Research, Sarah Cannon Research Institute, commented on the...
Expert Point of View: William Kevin Kelly, DO
Formal discussant of the CheckMate 650 trial, William Kevin Kelly, DO, Professor of Medical Oncology at the Sidney Kimmel Cancer Center and Jefferson Health in Philadelphia, commented on the combination therapy’s toxicity. “The discontinuation of study drug was significant. An important issue is...
Expert Point of View: Ian Davis, MBBS, PhD, FRACP, FAChPM, and Howard I. Scher, MD
Although ARCHES was a positive trial, the results may not signal a practice change at this time, according to formal discussant Ian Davis, MBBS, PhD, FRACP, FAChPM, of Monash University Eastern Health Clinical School, Melbourne. “We should probably not change practice yet on the basis of these...
AACR 2019: Phase I Trial Evaluates LOXO-195 in Patients With NTRK-Positive Solid Tumors
The investigational anticancer therapeutic LOXO-195, which targets a family of proteins called tropomyosin receptor kinases (TRKs), was safe, tolerable, and showed signs of clinical activity in patients who had solid tumors that harbored NTRK gene fusions and had become resistant to other...
AACR 2019: Higher BMI Before Age 50 May Increase Risk of Pancreatic Cancer
A higher body mass index (BMI) before age 50 may be more strongly associated with pancreatic cancer mortality risk than excess weight at older age, according to the results of a study presented by Jacobs et al at the American Association for Cancer Research (AACR) Annual Meeting 2019 (Abstract...
FDA Pipeline: Mammography Policies, Designations for Leukemias and Myelodysplastic Syndrome
This week, the U.S. Food and Drug Administration (FDA) announced policy changes to modernize mammography policies and issued a Breakthrough Therapy designation, an Orphan Drug designation, and an investigational new drug application. FDA Advances Policy Changes to Modernize Mammography Services...
Looking for Trusted Patient Information Resources?
CHECK OUT ASCO Answers patient education materials in the ASCO University Bookstore. ASCO Answers includes award-winning guides, fact sheets, and booklets covering a broad range of important and popular topics in cancer care. Bulk quantities of these high-quality print materials are available at...
Prostatectomy vs Watchful Waiting: Clinical Dilemma Centers on Aggressive vs Indolent Disease
THE MANAGEMENT of localized prostate cancer remains controversial. Although the widespread use of prostate-specific antigen (PSA) testing has resulted in a dramatic increase in the diagnosis and treatment of prostate cancer, many men do not benefit from intervention because the disease is either...
Expert Point of View: Ajay K. Nooka, MD, MPH
THE ASCO POST asked Ajay K. Nooka, MD, MPH, Associate Professor, Division of Bone Marrow Transplant at Winship Cancer Institute, Emory University, to comment on studies involving daratumumab. “After the phase III SWOG S0777 trial demonstrated a survival benefit with a 3-drug induction regimen...
New ASCO Guideline on Head and Neck Cancer Clarifies Lymph Node Management
A NEW ASCO guideline, “Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx: ASCO Clinical Practice Guideline,” aims to clarify issues in lymph node management.1 “This guideline represents a true multidisciplinary synthesis of some important new information about...
FDA Commissioner Scott Gottlieb, MD, Resigns
ON MARCH 5, 2019, Scott Gottlieb, MD, announced his resignation as Commissioner of the U.S. Food and Drug Administration (FDA), a post he began in 2017. Dr. Gottlieb’s resignation will be effective in April. In a resignation letter to Alex M. Azar II, Secretary of Health and Human Services (HHS),...
American Society of Breast Surgeons Recommends Genetic Testing for Newly Diagnosed Patients With Breast Cancer
IN A MOVE that is a significant departure from current testing recommendations, the American Society of Breast Surgeons (ASBrS) recommends that genetic testing be available to all individuals newly diagnosed with breast cancer.1 The new recommendations expand on common restrictions by the National...
Expert Point of View: Siwen Hu-Lieskovan, MD, PhD
DISCUSSANT OF the CheckMate 384 trial, Siwen Hu-Lieskovan, MD, PhD, Director of Solid Tumor Immunotherapy at the Huntsman Cancer Institute, University of Utah, called the short-term safety data “convincing.” However, she noted that the long-term impact of intermittent, lower-minimum concentration...
Ultradeep Next-Generation Sequencing in Patients With Lung Cancer
A new method of determining the sequence of molecules in DNA can be used to detect small fragments of cancerous genetic material in blood samples from patients with lung cancer with a high degree of accuracy, according research published by Li et al in Annals of Oncology. Liquid Biopsies and...
Genomic Testing Associated With Lower Health-Care Costs in Patients With High-Risk Breast Cancer
New research published by Dinan et al in JNCCN—Journal of the National Comprehensive Cancer Network provides evidence that genomic recurrence score testing using the 21-gene assay is associated with decreased cancer care costs in real-world practice among certain patients with breast...
